Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00967382 · ClinicalTrials.gov registry record · Phase 3

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

A Phase 3 study of Pregnancy and Pregnancy Complications, sponsored by Ottawa Hospital Research Institute.

Completed
Registry status
Phase 3
Development phase
292
Enrollment target
12
Study locations

NCT00967382 is a Phase 3 study of Pregnancy and Pregnancy Complications that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 292 participants, below the 871-participant average among 191 other Pregnancy trials with a reported enrollment target (66% lower). The trial reports 12 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00967382, a Phase 3 study of Pregnancy and Pregnancy Complications, has completed, sponsored by Ottawa Hospital Research Institute.

COMPLETED
Registry status
Phase 3
Development phase
292 participants
Enrollment target
12
Study locations

Study Summary

The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent thrombosis in the leg veins, pulmonary arteries and placental vessels, thereby reducing the risk of deep vein thrombosis, pulmonary embolism (PE), intrauterine growth restriction (IUGR), preeclampsia, miscarriage and stillbirth?

Conditions Studied

Pregnancy Pregnancy Complications Thrombophilia

Interventions

  • DRUG dalteparin sodium

Study Locations (12)

Ontario

  • Hamilton Health Sciences Centre - Hamilton
  • The Ottawa Hospital, Civic Campus - Ottawa
  • Mount Sinai Hospital - Toronto
  • Women's College Health Sciences Centre - Toronto

Quebec

  • SMBD Jewish General Hospital - Montreal
  • St Mary's Hospital Centre - Montreal
  • CHA, Hopital Enfant Jesus - Québec

Missouri

  • Saint Louis University - St Louis

Utah

  • University of Utah Health Sciences Centre - Salt Lake City

Alberta

  • Royal Alexandra Hospital - Edmonton

Nova Scotia

  • QEII Health Sciences Centre - Halifax

Saskatchewan

  • Royal University Hospital - Saskatoon

Trial Details

FieldValue
Enrollment Target 292 participants
Start Date 2000-07
Est. Completion 2014-03
Phase Phase 3

Sponsor

Ottawa Hospital Research Institute

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00967382

The ClinicalTrials.gov registry entry for NCT00967382 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 871-participant average among 191 other Pregnancy trials with a reported enrollment target (66% lower). The listed sponsor is Ottawa Hospital Research Institute, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which dalteparin sodium is the first listed.

NCT00967382 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Ontario, Quebec, Missouri.

Frequently Asked Questions

What is clinical trial NCT00967382 about?

NCT00967382 is a clinical study titled "TIPPS: Thrombophilia in Pregnancy Prophylaxis Study". The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent t...

What is the current status of trial NCT00967382?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2000-07. Estimated completion is 2014-03.

What conditions does trial NCT00967382 study?

This clinical trial studies the following conditions: Pregnancy, Pregnancy Complications, Thrombophilia.

What interventions are being tested in trial NCT00967382?

The interventions under investigation include: dalteparin sodium (DRUG).

Who is sponsoring clinical trial NCT00967382?

This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00967382 being conducted?

This trial has 12 study locations across Missouri, Utah, Alberta, Nova Scotia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pregnancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pregnancy

All registered trials for this condition

Pregnancy Complications

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.